SHORT, INTERMEDIATE AND LONG TERM RESULTS OF AHMED GLAUCOMA VALVE IMPLANTATION
Published 2022
- 26th ESCRS Winter Meeting
Reference: P272
| Type: Abstracts
| DOI:
10.82333/zj07-6481
Authors:
Nader Nassiri* 1
, Maryam Yadgari 2
, Kourosh Sheibani 2
, Sara Kavousnezhad 3
1Ophthalmology,Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences,Tehran,Iran, Islamic Republic Of, 2Ophthalmology,Basir Eye Health Research Center,Tehran,Iran, Islamic Republic Of, 3Ophthalmology,Vanak Eye Surgery Center,Tehran,Iran, Islamic Republic Of
Purpose
To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation for glaucomatous eyes in short, intermediate, and long term follow up periods.
Setting
Imam Hossein Medical Center, Tehran, Iran.
Methods
In this retrospective study 76 eyes of 76 patients who underwent AGV insertion in Imam Hossein Medical Center, Tehran, Iran, between January 2008 and March 2017 with at least three years of followup were included. At each visit complete ophthalmic examination was performed and the success rate of surgery was assessed. Surgical success was defined as 5 ≤ IOP ≤ 21 mmHg and at least 20 % reduction in IOP without any glaucoma medication (complete success), or with the use of anti glaucoma medication (qualified success). The sum of complete and qualified success was reported as cumulative success.
Results
The mean age of patients was 53.18 ± 16.92 years and the mean duration of follow up was 3.27 ± 2.36 years (range: 1-5 years). The complete surgical success rate was 20 % at 1 year, 18 % at 2 years, 16 % at 3 years, 15 % at 4 years, and 8 % at 5 years of followup and there was no medication free patient at more than 5 years followup. The cumulative success rate was 91 %, 88 %, 84 %, 80 %, and 77 % at 1 to 5 years of followup respectively.
Conclusion
Ahmed glaucoma valve (AGV) implantation for glaucomatous eyes results in acceptable IOP reduction and less medication need in short, intermediate, and long term follow up periods.